EP2968246A4 - Omega-3-pentaensäure-zusammensetzungen und verfahren zur verwendung - Google Patents

Omega-3-pentaensäure-zusammensetzungen und verfahren zur verwendung

Info

Publication number
EP2968246A4
EP2968246A4 EP13878433.5A EP13878433A EP2968246A4 EP 2968246 A4 EP2968246 A4 EP 2968246A4 EP 13878433 A EP13878433 A EP 13878433A EP 2968246 A4 EP2968246 A4 EP 2968246A4
Authority
EP
European Patent Office
Prior art keywords
omega
methods
pentanoic acid
acid compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13878433.5A
Other languages
English (en)
French (fr)
Other versions
EP2968246A1 (de
Inventor
Abdel Aziz Fawzy
George Bobotas
Roelof Rongen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Inc
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Publication of EP2968246A1 publication Critical patent/EP2968246A1/de
Publication of EP2968246A4 publication Critical patent/EP2968246A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Edible Oils And Fats (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP13878433.5A 2013-03-13 2013-12-17 Omega-3-pentaensäure-zusammensetzungen und verfahren zur verwendung Withdrawn EP2968246A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780948P 2013-03-13 2013-03-13
PCT/US2013/075661 WO2014143272A1 (en) 2013-03-13 2013-12-17 Omega-3 pentaenoic acid compositions and methods of use

Publications (2)

Publication Number Publication Date
EP2968246A1 EP2968246A1 (de) 2016-01-20
EP2968246A4 true EP2968246A4 (de) 2016-08-03

Family

ID=51537458

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13878433.5A Withdrawn EP2968246A4 (de) 2013-03-13 2013-12-17 Omega-3-pentaensäure-zusammensetzungen und verfahren zur verwendung
EP14779339.2A Withdrawn EP2986148A2 (de) 2013-03-13 2014-03-12 Zusammensetzungen mit docosapentansäure und verfahren zur verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14779339.2A Withdrawn EP2986148A2 (de) 2013-03-13 2014-03-12 Zusammensetzungen mit docosapentansäure und verfahren zur verwendung

Country Status (4)

Country Link
EP (2) EP2968246A4 (de)
JP (2) JP2016518315A (de)
CA (2) CA2905671A1 (de)
WO (4) WO2014143272A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6750831B2 (ja) * 2014-12-15 2020-09-02 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． 非アルコール性脂肪性肝疾患の処置
CN106692973A (zh) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
CA3023648C (en) * 2016-05-10 2023-11-28 Shenzhen Hightide Biopharmaceutical, Ltd. Pharmaceutical composition of berberine with epa and dha
JP2020508285A (ja) * 2017-02-09 2020-03-19 エス．エル．アー． ファーマ アーゲー 遊離脂肪酸としての高純度のエイコサペンタエン酸は、潰瘍性大腸炎患者の便中カルプロテクチンレベルを減少させ、臨床的再発を防止する
CN107006809B (zh) * 2017-04-11 2020-06-09 江南大学 一种有降血脂作用的醋洋葱制品及制备方法
JP7099821B2 (ja) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物
AU2020370081A1 (en) * 2019-10-25 2022-06-02 Nuseed Pty Ltd. Enriched polyunsaturated fatty acid compositions
CN118993893B (zh) * 2024-08-07 2025-06-17 蓝平 一种epa衍生物及其制备方法与用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (de) * 2005-04-21 2006-10-25 N.V. Nutricia Verfahren zur Behandlung oder Vorbehandlung von Lungeninsuffiziens
WO2008032949A1 (en) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1622467A1 (de) * 2003-05-05 2006-02-08 Denofa AS Fischöle mit geändertem fettsäuregehalt, verfahren zu deren herstellung und deren verwendung
EP1656839A1 (de) * 2004-11-11 2006-05-17 N.V. Nutricia Nahrung, die eine Lipidmischung enthält
CA2588166A1 (en) * 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
WO2007058523A1 (en) * 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
RU2505292C2 (ru) * 2009-02-10 2014-01-27 Амарин Фармасьютикалз Айрлэнд Лимитед Способы лечения гипертриглицеридемии
CN102421422A (zh) * 2009-03-09 2012-04-18 普罗诺瓦生物医药挪威公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
CN107233337A (zh) * 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
EP3335713B1 (de) * 2009-10-29 2022-08-31 Acasti Pharma, Inc. Konzentrierte therapeutische phospholipid-zusammensetzungen
US20120302639A1 (en) * 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
WO2013033618A1 (en) * 2011-09-02 2013-03-07 Arctic Nutrition As Lipid compositions with high dha content

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (de) * 2005-04-21 2006-10-25 N.V. Nutricia Verfahren zur Behandlung oder Vorbehandlung von Lungeninsuffiziens
WO2008032949A1 (en) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014143272A1 *

Also Published As

Publication number Publication date
JP2016512544A (ja) 2016-04-28
WO2014143275A1 (en) 2014-09-18
CA2905671A1 (en) 2014-09-18
CA2905795A1 (en) 2014-10-09
WO2014143272A1 (en) 2014-09-18
WO2014158256A1 (en) 2014-10-02
EP2968246A1 (de) 2016-01-20
EP2986148A2 (de) 2016-02-24
JP2016518315A (ja) 2016-06-23
WO2014165190A3 (en) 2015-01-29
WO2014165190A2 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
FR26C1005I1 (fr) Compositions et procédés de modulation de l'expression de l'apolipoprotéine c-iii
FR26C1011I1 (fr) Composés thérapeutiquement actifs et leurs méthodes d'utilisation
EP2861227A4 (de) Omega-3 pentaensäurezusammensetzungen und verfahren zur verwendung
MA41999A (fr) Compositions d'acide obéticholique et procédés d'utilisation
EP2964235A4 (de) Antimikrobielle antibiofilm-zusammensetzungen und verfahren zur verwendung davon
IL249821A0 (en) Omega-3 fatty acid ester compositions
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP2841443A4 (de) Serpinc1-irna-zusammensetzungen und verfahren zur verwendung davon
EP2915557A4 (de) Retinsäure-mikronadel
EP3735963C0 (de) Selbstemulgierende zusammensetzung von omega-3-fettsäure
EP2961382A4 (de) Topische zusammensetzungen und verfahren zur verwendung davon
EP2834322A4 (de) Biokohlezusammensetzungen und verfahren zur verwendung davon
EP2892562A4 (de) Anti-mcam-antikörper und zugehöriges verfahren zur verwendung
EP2983661A4 (de) Formulierungen von oxabicycloheptanen und oxabicycloheptenen
EP2968280A4 (de) Substituierte triazolopyridine und verfahren zur verwendung davon
MA43385A (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
EP2996694A4 (de) Cenicriviroc-zusammensetzungen sowie verfahren zur herstellung und verwendung davon
MA43282A (fr) Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
EP3113613A4 (de) Liponsäure-cholinester-zusammensetzungen und verfahren zur verwendung davon
FR3009208B1 (fr) Tete de distribution et d'application
EP2897639A4 (de) Verbesserte impfstoffzusammensetzungen und verfahren zur verwendung
MA42118A (fr) Benzamides substitués et leurs méthodes d'utilisation
EP2971042A4 (de) Flavivirusneutralisierende antikörper und verfahren zur verwendung davon
EP2988764A4 (de) Zusammensetzungen gegen schuppen und verfahren zur verwendung davon

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150930

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160704

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/232 20060101ALI20160628BHEP

Ipc: A61K 31/202 20060101AFI20160628BHEP

Ipc: A61K 9/48 20060101ALI20160628BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170201